Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Superlab Suisse opens state-of-the-art facility in Basel, fostering new spaces for scientific breakthroughs

Superlab Suisse

For life sciences and biotech companies, access to affordable dedicated lab spaces is hard to come by. Labs are prohibitively expensive to build and operate, posing significant financial barriers to innovation and research. A cutting-edge new alternative is being offered by Superlab Suisse, a leading provider of innovative laboratory and research spaces that today announces the grand opening of its newest facility in Basel. With this new facility, Superlab Suisse becomes the largest private lab space in Switzerland. Opening in July 2024, following the success of the Lausanne location supported by Biopôle Lausanne and InnoVaud, the expansion marks a significant milestone in Superlab Suisse's mission to provide research infrastructure to Switzerland's dynamic life sciences sector. Forging ahead with its successful partnership with Swiss Prime Site, Superlab Suisse is set to open the door for huge commercial opportunities in the ideally suited location of Basel, a booming biotechnology hub and home to over 700 companies including pharmaceutical giants like Novartis and Roche. The new facility, nestled within the bustling Stücki Park with neighbours like Tech Park Basel, Lonza, Medartis, NBE, and Boehringer Ingelheim, offers ready-to-use laboratory spaces equipped with the latest technology and essential operational support services, allowing teams to channel their resources into scientific research rather than lab operations. Spanning over 4770 square metres, it promises to be a nucleus of scientific collaboration and breakthrough, redefining laboratory services in Basel. "We are thrilled to bring Superlab Suisse's innovative platform to Basel, the city of Pharma," says Xi Zhang, CEO of Superlab Suisse. “Our holistic solution frees scientists from operations headaches, so they can save time and focus on science. We service, you discover”. Life sciences and biotech companies have until now lacked the widely accepted lab solutions that have benefitted industries such as tech and finance. Universities have typically been the only viable option, with lab construction and operation requiring significant upfront investments — costs which redirect attention away from research and delay progress in getting products to market. Superlab Suisse's serviced BSL1 and BSL2 labs provide a new industry standard of lab solution. Users in one location such as Basel also gain access to facilities in Lausanne and other locations. By delivering ready to move in lab solutions for life science companies of all sizes, including startups, scale-ups, and corporates, Superlab Suisse eliminates the hurdles of lab construction and operation. One of the first companies to secure their space at the opening is Skyhawk Therapeutics, which has recently announced a research collaboration with Ipsen focusing on RNA targeting in rare neurological diseases. In addition to the Basel location, Superlab Suisse continues its commitment to innovation with plans for a third site in Zurich Schlieren. This new facility, scheduled to open in March 2025, will cater to the diverse needs of start-ups, spin-offs, and established companies in the life sciences sector, further solidifying Superlab Suisse's position as a leader in laboratory-as-a-service solutions. This one-stop solution not only solves the true problems of life science companies but also attracts like-minded innovators to meet and collaborate. Superlab is expanding this year to more cities in Europe, the US, and Asia, embodying a borderless lab concept because life science benefits humanity as a whole. Dr. Rajwinder Lehal, CEO of biotech business Cellestia commented: “Superlab is exactly the place which the scientific community needs, where we can concentrate on our work without being distracted by construction or operation. Superlab provided us with state of the art infrastructure and equipment that we needed to hit the ground running from day 1.” Emmanuel Savioz, CEO & Chairman, Tigen Pharma commented: “Superlab is a great place to work in a vibrant scientific community. Our team at Tigen can focus on growth, supported by state-of-the-art facilities, latest equipment and a competent and fun Superlab team to support on-site”. About Superlab Suisse AG Superlab Suisse AG offers innovative laboratory solutions through its "Lab as a Service" business concept. With state-of-the-art facilities, professional services, and financing support, Superlab Suisse empowers companies in the biotech, pharma, and medtech sectors to focus on research and innovation. About Swiss Prime Site AG Swiss Prime Site is the largest real estate company in Switzerland and one of the leading commercial property companies in Europe. The real estate portfolio spanning across densely populated areas is valued at approximately CHF 26 billion and includes own properties – with about CHF13 billion commercial properties and development projects – as well as ones managed on behalf of third parties with about CHF 13 billion AuMs invested in residential and commercial buildings. Contact Details Superlab Suisse Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://superlabsuisse.com/

June 25, 2024 07:00 AM Eastern Daylight Time

Image

Roberts & Ryan Inc. expands its internship program in partnership with the Boys and Girls Club of Harlem.

Roberts & Ryan, Inc.

Roberts & Ryan, Inc., America’s first Service-Disabled Veteran-Owned (SDVO) broker-dealer, announced the expansion of its summer internship program, which recently accepted 13 candidates from a diverse pool of students from a variety of schools and backgrounds. The expansion reflects the company’s commitment to supporting veterans and underprivileged youth. “At Roberts & Ryan, we believe that supporting future generations of financial professionals is important to the long-term success of our industry. This year’s internship class was bolstered by our relationship with the Boys & Girls Club of Harlem, who recommended two exceptional candidates, creating more opportunities for diverse talent in the financial services industry,” said Brian Rathjen, President of Roberts & Ryan. Seven interns completed Roberts & Ryan's internship program in 2023, a number the firm nearly doubled in 2024 due to increased student demand. Roberts & Ryan runs two internship cohorts per year to provide students from a variety of backgrounds with real-world experience in the financial services industry. Interns collaborate with experienced professionals on projects that demonstrate a range of services provided by Roberts & Ryan, from secondary equity and fixed income trading to debt and equity capital markets, business development, compliance, and marketing. Roberts & Ryan was recently approved for membership by the New York Stock Exchange, and summer interns have access to its iconic trading floor. "Breaking into the financial services industry can be a challenge, as most entry-level positions require either previous work experience or a professional connection with someone in the industry. We believe that our program provides our interns with both,” said Edward D’Alessandro, Chief Executive Officer of Roberts & Ryan. Roberts & Ryan is committed to increasing access to opportunities in the financial sector by finding high-quality candidates for their internship program. Through the program, interns gain valuable experience, make important connections, and build a talent stack for a successful career in finance. For current undergraduate and graduate students interested in participating in next year’s internship program, please email your resume to info@roberts-ryan.com. About Roberts and Ryan, Inc. Roberts & Ryan, Inc. is a Service-Disabled Veteran Owned (SDVO) broker-dealer with execution capabilities in the capital markets, equities, and fixed-income trading. The firm was founded in 1987 by a United States Marine Corps Vietnam combat veteran and Purple Heart recipient. With over $2 million in committed donations, Roberts & Ryan is active in donating to charitable foundations that make significant positive impacts in the lives of Veterans and their families, primarily focusing on general wellness, mental health, and career transition. To learn more about Roberts & Ryan, please visit www.roberts-ryan.com. Contact Details Michael C. Del Priore +1 646-859-4061 mdelpriore@roberts-ryan.com Company Website https://www.roberts-ryan.com

June 13, 2024 09:00 AM Eastern Daylight Time

Image

Stupid Cancer Announces CancerCon Live 2024 in Austin, Texas

Stupid Cancer

Stupid Cancer, the leading nonprofit organization dedicated to empowering everyone affected by adolescent and young adult (AYA) cancer, is thrilled to announce that CancerCon Live 2024 will take place in Austin, Texas for the first time ever. This landmark event, scheduled for August 15 - 18, 2024 at the Hyatt Regency Austin, promises to bring together hundreds of young adult cancer patients, survivors, caregivers, and advocates from across the country to share their experiences, gain valuable insights/resources, and build lasting connections. “We look forward to creating an unforgettable experience that empowers young adults affected by cancer and helps them connect with others who truly understand their journey.” says Alison Silberman, CEO of Stupid Cancer. CancerCon Live is the premier annual gathering for the AYA cancer community, offering a unique blend of education, support, and empowerment. This year's event in Austin will feature: Keynote Speakers: Hear from leading voices in the AYA cancer community, including survivors, healthcare professionals, and advocates, sharing their stories and insights on topics ranging from advancements in cancer treatment to survivorship challenges. Workshops and Panels: Participate in interactive sessions on a wide range of topics tailored to the unique needs of AYA cancer patients, survivors, and caregivers, covering mental health, fertility preservation, advocacy, career development, and more. Meet the AYA Community: Dedicated time for attendees to connect with peers, build lasting friendships, and expand their support networks in a supportive and inclusive environment. Exhibit Hall: Explore resources, products, and services from leading organizations committed to supporting the AYA cancer community as well as a few local small businesses. Social Events: Enjoy fun and engaging social activities designed to foster connections and create memorable experiences with some local Austin flavor. Local excursions: Attendees will have the opportunity to explore the city’s unique attractions, including Bat Watching under Congress Bridge and unlimited Skee-Ball at Full Circle Bar, to name a few, all while engaging in meaningful activities that support their personal and collective growth. “Austin’s dynamic and inclusive culture aligns perfectly with our mission to build a strong, supportive community for AYA cancer patients and survivors. We look forward to welcoming everyone to what promises to be our most impactful CancerCon yet,” says Eddie Mouradian, Director of Development. For over a decade, Stupid Cancer has brought together hundreds of patients, survivors, caregivers, advocates, and health professionals at the largest gathering of the AYA community - CancerCon (R). Now gathering both online and off, every CancerCon event is an immersive experience, led by transformative connection and education. The majority of conference attendees are AYA (age 15-39) cancer patients and survivors, but caregivers and health professionals of all ages are also welcome. CancerCon Live is hosted in a different US city each year as we seek to make the event always be within reach of our community at all times. Registration for CancerCon Live 2024 is now open. To register or learn more about the event, please visit cancercon.org. About Stupid Cancer Stupid Cancer’s mission is to help empower everyone affected by adolescent and young adult cancer by ending isolation and building community. Through innovative programming and strategic communications, the organization aims to provide support, resources, education, and a sense of community both online and in-person. For more information, please visit stupidcancer.org. For media inquires, contact: media@stupidcancer.org About Stupid Cancer:Stupid Cancer's mission is to help empower everyone in the adolescent and young adult (AYA) community by ending isolation and building community. Contact Details Alison Silberman +1 646-868-0087 media@stupidcancer.org Company Website https://stupidcancer.org/

June 12, 2024 02:39 PM Eastern Daylight Time

Image

Therma Bright’s Investment Case Just Got Stronger As Approval On Permanent Insurance Codes Gets Closer

TBRIF

Therma Bright (TSXV:THRM) (OTCQB:TBRIF), a developer of a wide range of leading edge, proprietary diagnostic and medical device technologies that address some of today's most important medical and healthcare challenges, appears to be positioned for major growth based on one important upcoming catalyst. For some background, Therma Bright (TSXV:THRM) (OTCQB:TBRIF) sells Venowave, a compact, battery operated peristaltic pump that generates a wave-form motion. When worn below the knee and strapped to the calf, the resulting compression of the calf causes an increased upward volumetric displacement of venous and lymph fluid. The Venowave is FDA approved for 10 indications, including: Management of Post Thrombotic Syndrome, Prevention of Deep Vein Thrombosis (DVT / blood clots), treatment of Chronic Venous Insufficiency, as well as other conditions related to poor circulation in the extremities.It seems that the company is set to receive a newly issued, HCPCS Level II code to identify it’s Venowave device,which will be instrumental in driving revenue growth. HCPCS codes are a set of health care procedure codes used in the United States to standardize the reporting of medical procedures, services and devices. These codes are essential for billing and reimbursement purposes within the Medicare and Medicaid programs, and are also used by other healthcare insurers in the United States, including private insurance companies. Additionally, a preliminary Medicare Payment determination will be made for this new HCPCS code. If the Venowave is purchased outright, Medicare and Medicaid will reimburse $1,199 USD. If the unit is rented to the patient, Medicare and Medicaid will pay $78.05 USD / month for up to 13 months, for a total of $819.55 USD. These are very favourable numbers for Therma Bright when taking into account the manufacturing cost of Venowave. Additionally, private insurers such as blue cross blue shield, UnitedHealth Group, etc., also use these codes as guidelines to determine reimbursement payouts. Why is this so important? Previously, Venowave was placed into the E0676 HCPCS code. E0676 is a miscellaneous code with no set reimbursement, meaning that when Venowave is billed for under this code, Medicare and Medicaid, as well as private insurance companies will default to a $0 reimbursement. While it is possible to submit a package of medical necessity under this code, with a detailed explanation of the patients’ condition and why it should be reimbursed, the reality is that most physicians or prescribing parties will not go through this exercise as they are not reimbursed for the time and trouble it takes. Therma Bright experienced a similar situation with the temporary codes it was approved to sell Venowave under in 2023 – Without the prescribing party submitting a package of medical necessity, Venowave by default will not be paid for. Additionally, these reimbursement issues are a barrier to prescribing parties recommending Venowave, as they are not able to tell their patients if the device will be paid for. Physicians tend to shy away from prescribing devices in these categories, as they could leave their patient with a large unexpected medical bill, reflecting badly on the prescribing party. This new HCPCS code combined with the preliminary payment determination establishes a fixed payout for Venowave across public and private insurers in the United States, eliminating friction in payments as well as hesitancy by the prescribing parties in recommending the device. Therma Bright expects to receive this new HCPCS code and payment determination after the biannual CMS meeting which was held at the end of May, 2024. Venowave differentiates itself from other available compression products in a number of ways. Currently, pneumatic devices and simple products that squeeze the leg make up the majority of the compression market. Inexpensive portable compression devices simply squeeze and release the calf, and do not actively move fluid upwards towards the heart. Sequential compression devices are proven very effective, however they are not portable. Sequential compression devices have tubes attached to an air compressor which inflates chambers in sequence, providing sequential compression. Typically these devices can only be used while lying in bed, on a couch or in a similar position, and do not allow the patient to remain ambulatory. Venowave combines the best of both worlds, providing sequential compression without the use of tubes or wires, allowing the patient to remain completely ambulatory while receiving treatment. Additionally, Venowave is quiet, so patients can continue to receive treatment while they are sleeping or otherwise resting. Currently in the United States an estimated 25 million people are living with some form of Chronic Venous insufficiency. Most go untreated or rely on simple compression stockings for some form of minor relief, as proper treatment via sequential compression devices is too cumbersome and expensive. The issuance of this new HCPCS code and payment determination opens up these patients to the Venowave, a new and portable form of treatment that will not cost them anything out of pocket. This market alone, along with the management of Post Thrombotic Syndrome and prevention of primary thrombosis is potentially huge. Additionally, Therma Bright is working towards securing reimbursement for DVT prevention. While Medicare and Medicaid do not pay for DVT prevention, private insurers do. Therma Bright is confident that the issuance of this new HCPCS code and payment determination will help patients access Venowave for DVT prevention via their private health insurance, which is another huge addressable market in the United States. During the last year, Therma Bright has been meeting with potential distributors across the United States. Many have indicated interest in the Venowave pursuant to a positive outcome with regards to the HCPCS coding. Therma Bright currently has over 2000 Venowave units in inventory, which they expect can be moved right away upon the issuance of the HCPCS code. After these initial 2000 units are sent to distributors, placed on patients, and reimbursement received, Therma Bright conservatively estimates moving 500-1000 units / month. Given the high margin on Venowave, this will fare well for the company. As Venowave is a high margin product, the company is looking at the possibility of setting up a manufacturing operation in either the U.S, Canada or Mexico which would allow it to sell to the VA in the US. This would open up yet another large market for Venowave in the United States. For investors who may be interested in Therma Bright, it is important to note that Venowave isn’t its only product. The company also has respiratory health and consumer health product portfolios. The respiratory health product portfolio features the Digital Cough Test (DCT) app created by Therma Bright (TSXV:THRM) (OTCQB:TBRIF) and AI4LYF. The app uses artificial intelligence to detect multiple respiratory diseases by analyzing a person’s cough sound and has shown a high accuracy rate. The app is currently in the process of securing a 513g FDA clearance, which will allow the company to charge for Remote Therapeutic Monitoring (RTM) and be used for patient reimbursement. The consumer health product portfolio features devices designed for pain relief, cold sore prevention and insect bite relief. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and expects to be compensated by Therma Brite to assist in the production and distribution of content related to TBRIF. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Inc Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://RazorPitch.com

June 12, 2024 06:00 AM Eastern Daylight Time

Busting the Myths Around Weight Loss Medication

YourUpdateTV

Obesity is one of the most common chronic health issues in the U.S. today, and can lead to or exacerbate many other significant physical and mental health challenges, including type 2 diabetes, heart disease and depression. But GLP-1 injections are an impactful new tool that can help people on their weight loss journey. Recently, Dr. Craig Primack, the Senior Vice President of Weight Loss at Hims and Hers, participated in a nationwide satellite media tour to discuss the impact of obesity, common myths surrounding weight loss medications, and personalized options that can help. A video accompanying this announcement is available at: https://youtu.be/NGNz92bi7nY Research shows that even just 5-10% of body weight loss can improve blood pressure, blood sugar, cholesterol, joint pain, sleep apnea, and other weight-related conditions. Weight loss drugs like GLP-1 medication are not only an exciting tool in the weight loss tool belt but can help to address the challenges associated with obesity. GLP-1 injections can support healthy weight loss along with a reduced calorie diet and increased exercise. Some common myths regarding weight loss medications, include: ● Many people assume that weight loss medications are magic. Weight loss drugs can be excellent tools for decreasing hunger and therefore reducing overall calorie intake, but their effects are not instant and should be combined with a healthy lifestyle approach, including a balanced diet and regular exercise. ● People also assume that the injections are painful. The injection is a very small needle that goes just under the skin. It feels like a small pinch, and is quite painless. For the most part, people do great with self-administering GLP-1 injections. ● Lastly, many people think that weight loss drugs come with dangerous side effects. Like all medications, there is a risk of side effects, but there are really only three common side effects associated with GLP-1’s, and they are generally mild: nausea, heartburn, and constipation. The benefits of these drugs far outweigh the risks for many, especially when compared to the health risks associated with being overweight. Hims & Hers’ personalized approach means custom treatment for individual needs to minimize these side effects. Known for its holistic, personalized approach to health and wellness, Hims & Hers is now offering access to GLP-1 injections designed for affordability and effectiveness. These are the four things you should know. ● Hims & Hers’ weight loss program is tailored to an individual’s needs and includes customized medication kits or GLP-1 medication, as determined appropriate by the healthcare provider. ● The science-backed and doctor-developed program is available 100% online for as little as $199 a month. ● Through the app, a licensed healthcare provider will work with you to decide the recommended treatment, plus provide realistic nutritional tips with easy to follow snack and meal ideas. ● Hims & Hers takes the safety of each customer very seriously. The pharmacies the brand works with provide sterile, single-use syringes with each GLP-1 shipment, and products are made with active ingredients from FDA regulated suppliers. And, injection medications are shipped in cold packs for temperature control in transit in the summer weather. For more information, visit hims.com/glp1 or forhers.com/glp1 About Dr. Craig Primack MD, FACP, FAAP, MFOMA Dr. Craig Primack is the Senior Vice President of Weight Loss at Hims & Hers. He completed his undergraduate studies at the University of Illinois and subsequently attended medical school at Loyola University — The Stritch School of Medicine. He completed a combined residency in Internal Medicine and in Pediatrics at Banner University- Phoenix, and Phoenix Children's Hospital. He received post-residency training in Obesity Medicine and is one of about 7,000 physicians in the U.S. certified by the American Board of Obesity Medicine. In 2006, Dr. Primack co-founded Scottdale Weight Loss Center in Scottsdale, Arizona, where he began practicing full-time obesity medicine. Scottsdale Weight Loss Center has grown since then to six obesity medicine clinicians in four locations around the greater Phoenix Metropolitan area.From 2019–2021, he served as president of the Obesity Medicine Association (OMA), a society of over 5,400 clinicians dedicated to clinical obesity medicine. He proudly served on the OMA board from 2010-2024, most recently as ex-officio trustee. Dr. Primack routinely does media interviews regarding weight loss and regularly speaks around the country educating medical professionals about weight loss and obesity care. He is co-author of the book, “Chasing Diets.” Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

June 11, 2024 11:37 AM Eastern Daylight Time

Video

NOVUS INK Advisors and Solidus Capital Group Team-up to Serve Growing Transatlantic Commercial Interests of Mid-Market Enterprises

NOVUS INK Advisors

NOVUS INK Advisors and Solidus Capital Group signed a services agreement today to provide integrated senior advisory and execution services to small-and mid-market enterprises amid thriving commercial interests between the United States and Europe. The two firms aim to accelerate client services by combining expertise and resources to support growth into new markets, encompassing management counsel, valuation, performance tracking, board advisory, marketing, communication, public and government affairs. The collaboration will enable NOVUS INK Advisors and Solidus Capital Group to meet the unique needs of global small-and mid-market enterprise clients operating across business-to-consumer, business-to-business, and business-to-government segments. The transatlantic economy is proving remarkably robust in the face of global economic and geopolitical disruptions. No two other regions in the world are as deeply integrated as the United States and Europe, according to the 2024 Transatlantic Economy Report from the U.S. Chamber of Commerce, AmCham EU, Johns Hopkins SAIS and the Transatlantic Leadership Network. The report states: "the $8.7 trillion transatlantic economy employs more than 16 million workers in mutually onshored jobs on both sides of the Atlantic. It is the largest and wealthiest market in the world, accounting for half of total global personal consumption and close to one-third of world GDP in purchasing power. Ties are solid in foreign direct investment, portfolio investment, banking claims, trade and affiliate sales in goods and services, digital links, energy, mutual R&D investment, patent cooperation, technology flows, and sales of knowledge-intensive services." The services agreement will be overseen by a committee chaired by Pia De Lima and Daniel Diaz, NOVUS INK Advisors' Managing Partners, and Andreas Dal Santo, Solidus Capital Group's Managing Director. NOVUS INK Advisors is based in Miami. Solidus Capital Group, affiliated with Atlantic Business Labs, is based in New York. NOVUS INK Advisors is a communication, public and government affairs lobbying firm. NOVUS INK Advisors' practice areas include Corporate, Band and Product Reputation, Business Strategy, Crisis and Reputation Risk, Financial Services, Investor Relations, Mergers & Acquisitions, Brand and Product Marketing Communications Strategy, and Public and Government Affairs. NOVUS INK Advisors is a registered lobbying firm. To learn more, visit: www.NovusInk.com. Solidus Capital Group specializes in management consulting, business valuation, and board advisory services for firms expanding into North America, Latin America, and Europe. It is spearheading an ecosystem of companies, consultants, and subject matter experts with experience from different industries and regions to support corporate and institutional clients' global strategies and growth into new markets. To learn more, visit www.solidus-capital.com. CONTACTS: NOVUS INK Advisors: client.services@NovusInk.com Solidus Capital Group: client.services@Solidus-Capital.com Contact Details NOVUS INK Advisors Client Services client.services@NovusInk.com Company Website https://www.novusink.com/about

June 11, 2024 09:30 AM Eastern Daylight Time

This One Company Is Working On A Breakthrough Approach To Revolutionize Pain Management

Autonomix Medical, Inc.

By Austin DeNoce, Benzinga Autonomix Medical (NASDAQ: AMIX) is a medical device company dedicated to transforming the diagnosis and treatment of diseases or disorders related to the nervous system. At the core of Autonomix's innovative approach is a first-in-class technology platform featuring a catheter-based microchip sensing array. This technology boasts an unprecedented ability to detect and differentiate neural signals with up to 3,000 times greater sensitivity than existing technologies. This breakthrough has paved the way for transvascular diagnosis and treatment of nervous system diseases virtually anywhere in the body, offering a new horizon of medical possibilities and market opportunities. Clinical Studies In Pancreatic Cancer Pain Autonomix has initiated its first clinical study targeting pancreatic cancer pain, marking a significant milestone in its ongoing medical innovation. Pancreatic cancer represents a considerable unmet medical need, particularly concerning pain management. Effective solutions in this area are critically needed, as current relief options for pancreatic diseases are limited to drugs like opioids. In light of that, the initiation of these clinical studies represents a crucial step toward addressing this substantial healthcare challenge for suffering patients. Market Opportunities In addition to addressing the pain relief needs of patients, Autonomix’s technology presents significant market opportunities across various medical fields. By accurately targeting the nervous system, Autonomix aims to address unmet needs and improve treatments for a wide range of conditions including but not limited to: Pancreatic Cancer Pain: The successful application of Autonomix's technology in pancreatic cancer pain management would not only help pancreatic cancer patients find relief from pain but also unlocks significant market potential. Pancreatic cancer pain management is part of a $2.2 billion market for pancreatic cancer treatment. Chronic Pain: This market presents a significant opportunity estimated at $75 billion. Conditions such as lower back pain, pelvic pain, urinary tract pain, digestive disorders and other tumor-related pain are prevalent and often inadequately managed with current therapies, particularly opioids. Autonomix's technology offers the potential to significantly reduce or eliminate the dependence on opioids, providing a safer and more effective solution for chronic pain management. Cardiovascular Diseases: With a market opportunity estimated at $23 billion, Autonomix's technology could revolutionize the treatment of conditions like hypertension and cardiovascular disease. By targeting the nervous system's role in these diseases, more precise and effective treatments could be developed. Pulmonary Diseases: Chronic obstructive pulmonary disease (COPD) is another area where Autonomix's technology could have a substantial impact. The market for COPD treatments is estimated to be around $18 billion with considerable growth ahead, driven by the need for more effective and less side-effect-prone therapies. Autonomix's approach could provide a new paradigm in managing this debilitating condition. Meeting Unmet Needs with Innovative Solutions Current drug therapies for many of these conditions often come with significant side effects and do not adequately address the underlying issues. Autonomix's technology offers a promising alternative by providing targeted, nerve-based treatments that could improve patient outcomes and quality of life. This innovative approach aligns with Autonomix's mission to dramatically enhance the lives of millions by enabling precise and effective nerve-targeted treatments. In doing so, Autonomix can both detect and ablate malfunctioning nerves in one simple procedure, effectively opening new treatment options in the field of electrophysiology. The Full Opportunity Autonomix Medical sits at the forefront of a potential revolution in medical treatment for diseases driven by the nervous system. The company’s advanced technology platform not only offers hope for better management of pancreatic cancer pain, but also opens the door to addressing numerous other conditions with significant unmet need. By providing physicians with powerful new tools for diagnosis and treatment, Autonomix is poised to make a profound impact on the future of healthcare. Featured photo by Irwan on Unsplash. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.We are initially developing our technology for pancreatic cancer pain, a condition that can cause debilitating pain and needs an effective solution. However, our technology constitutes a platform with the potential to address dozens of indications, including in cardiology, renal denervation and chronic pain management across a wide disease spectrum. Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the completion of patient enrollment in the trial and the Company’s ability to successfully meet the milestones set forth in this press release on a timely basis, if at all. Such forward-looking statements can be identified by the use of words such as ‘should,’ ‘may,’ ‘intends,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘forecasts,’ ‘expects,’ ‘plans,’ and ‘proposes.’Although Autonomix Medical, Inc. (or Autonomix) believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the offering circular filed with the U.S. Securities and Exchange Commission (“SEC”) on January 26, 2024. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details JTC Team, LLC autonomix@jtcir.com Company Website https://autonomix.com/

June 06, 2024 09:00 AM Eastern Daylight Time

Image

Halving of BTFS Storage Rewards

BitTorrent

Singapore, May 28, 2024 – To sustain the growth and success of the BitTorrent ecosystem, BTFS is set to implement a halving on the next round of rewards for storage miners on the BTFS network. From 00:00 (UTC) June 25, 2024, the daily rewards for storage miners on the BTFS network will be halved from 15 billion BTT to 7.5 billion BTT. The BitTorrent File System (BTFS) is a decentralized file storage system that utilizes blockchain technology and peer-to-peer transmission. It allows users to store their files across multiple nodes in a distributed manner, enhancing file security and reliability. BTFS also offers rapid file transfer and access, giving users greater convenience in managing and sharing files. By integrating key features of the BitTorrent Chain (BTTC), such as cross-chain connectivity and multichannel payment options, BTFS significantly enhances user experience. Currently, the BTFS network is experiencing rapid growth with over 8 million nodes across the network, including more than 6 million super miners, according to BTFS SCAN. To support the efficient operations of these nodes, BTFS initiated a rewards program and has provided an aggregate of 25 trillion BTT since the launch of BTFS Mainnet in 2019. Every two years, the BTFS rewards halving will occur causing the rewards for all storage miners across the network to be cut in half. (Halving roadmap) Moreover, halving will also prompt miners to improve node performance by optimizing node operation and reducing waste. In addition, an upgrade of the official website for the BTFS technical community and the release of BTFS v3.0 Mainnet will be scheduled in sync with the halving. These developments are expected to improve the efficiency of the BTFS protocol, expand the user base, and enhance its overall functionality. Looking ahead, BTFS is committed to continuously refining its storage rewards strategies. The goal is to expand the network of nodes participating in file storage on BTFS, providing developers with an efficient, secure, and reliable storage solution boosting both the capacity and the transaction efficiency of the BTTC network. About BTFS The BitTorrent File System (BTFS) is both a protocol and a web application that provides a content-addressable peer-to-peer mechanism for storing and sharing digital content in a decentralized file system, as well as a base platform for decentralized applications (Dapp). The BTFS team has been working on the latest network operations and BTT market sentiment, etc., to make a series of dynamic adjustments such as upload prices and airdrop reward schemes. About BitTorrent Founded with a leading peer-to-peer sharing technology standard in 2004, BitTorrent, Inc. is a consumer software company based in San Francisco. Its protocol is the largest decentralized P2P network in the world, driving 22% of upstream and 3% of downstream traffic globally. Its flagship desktop and mobile products, BitTorrent and µTorrent, enable users to send large files over the internet, connecting legitimate third-party content providers with users. With over 100 million active users, BitTorrent products have been installed on over 1 billion devices in over 138 countries worldwide. Since November 2018, TRON (TRX), Binance (BNB), and Bitcoin (BTC) holders have the opportunity to purchase one-year subscriptions of BitTorrent or µTorrent products, including Ads Free and Pro for Windows. Pro includes anti-virus and anti-malware screening, file converting and playability in HD. Users can visit bittorrent.com or utorrent.com to learn more. Website | Telegram | Medium | X | Media Contact John Chen press@bittorrent.com Contact Details John Chen press@bittorrent.com

May 28, 2024 07:53 PM Eastern Daylight Time

Image

Limula raises $6.8M to democratise access to life-saving Cell and Gene Therapies with Swiss-made manufacturing platform

limula

Over the last decade, several breakthrough Cell and Gene Therapy products have been approved in the USA and Europe to turn stem cells and immune cells into ‘living cures’, bringing hope to millions living with life-threatening conditions. However, these treatments remain out of reach for 98% of patients suffering from what are now curable conditions. This is in part due to complex, manual and costly manufacturing processes. Life science startup Limula announces today it has raised CHF6.2M ($6.8M) to take their solution for automating cell therapy manufacturing to the next stage of development. The oversubscribed seed round was led by LifeX Ventures, with participation from Verve Ventures, Zühlke Ventures, Oxford Seed Fund, Lichtsteiner Foundation, W.A. de Vigier Foundation, the founders, and a lineup of private individuals who have been supporting Limula’s vision from its inception. The company was founded in 2020 by Dr. Yann Pierson, Dr Luc Henry. Dr. Thomas Eaton to deliver a disruptive approach to the ‘ex vivo’ manipulation of cells, based on a novel technology. The trio witnessed that outdated manufacturing methods were a speed bump to the adoption of Cell and Gene Therapy products – like chimeric antigen receptor (CAR) T-cells. Combining breakthrough discoveries in genetic engineering and medicine led to a revolution in medicine, but boosting the patients’ own cells to produce a dose in a laboratory still requires too many manual steps. Highly skilled labour and sterile infrastructures represent the majority of the costs of a therapy, leading to a price tag of $500,000 or more per dose. As a result, these treatments are inaccessible for a majority of eligible patients. To combat this, Limula developed a modular solution for on-demand and at-scale manufacturing of cell therapies in a single device. By combining the functionalities of a bioreactor and a centrifuge into one single closed vessel, Limula’s proprietary solution can handle a wide range of volumes and cell numbers, removing transfer steps and therefore limiting stress, losses, and potential contamination. With a potential for scalability, it can be used by cell therapy providers in their transition from pre-clinical evaluation to clinical trials, and later commercial scale manufacturing of clinical-grade cell products. Luc Henry, co-founder and CEO of Limula said: "Our team is driven by the ambitious goal of developing tools that are based on a fundamentally novel way of manipulating cells outside of the body. Our technology supports manufacturing workflows that are impossible to automate with existing tools. We believe automation is the only route to scalability and digital traceability. These two aspects are keys unlocking the full potential of Cell and Gene Therapy, making them accessible to the many, not just the few”. Limula’s founders built a high performing multidisciplinary team, most recently joined by domain experts Olivier Waridel, former CEO of Cytiva-owned Biosafe, Caroline Boudousquié, former Head of Process Development at the Center for experimental therapeutics (CTE) of the University Hospital in Lausanne, and Maria Elena Grisostolo, former VP Operations at Lunaphore. After completing an initial proof of concept, the company launched a program to provide selected industry and academic partners access to the innovative platform ahead of its commercial launch. With the aim to broaden the scope of applications, Limula has signed partnerships with several research centres including San Raffaele Telethon Institute for Gene Therapy in Milan, Italy - a world-recognized centre of excellence for research and clinical translation of cell and gene therapy. Prof. Bernhard Gentner at San Raffaele Telethon Institute for Gene Therapy said: “We believe the solution Limula is advancing can support our current process development activities and later enable the manufacturing of these cell products at scale. We also see its potential in improving the status quo in Cell & Gene Therapy manufacturing in general, and in the field of haematopoietic stem cell transplantation in particular.” Dr Inaki Berenguer, managing partner at LifeX Ventures added: "We're thrilled to stand with the Limula team as they reinvent cell and gene therapy manufacturing. It's evident that production tools have lagged behind scientific and clinical advancements, particularly in terms of price and scalability. Limula's commitment to addressing these bottlenecks is crucial to enhancing accessibility for patients.” Looking ahead, Limula will use its new seed capital to significantly advance the development of the proprietary platform composed of a device and single use consumables, towards meeting good manufacturing practice (GMP) requirements. The solution developed by Limula is an enabling tool for a rapidly growing market. The potential of Cell and Gene Therapies to save the lives of millions of patients globally has generated significant interest – and investment – leading to a significant pipeline and several recent approvals by health authorities. Both industrial and academic players are now eager to adopt next-generation automated and scalable solutions with the shared goal to significantly increase market reach and broaden accessibility. About Limula Limula SA is a Life Science Tools company based in Lausanne, Switzerland, looking to disrupt the status quo in the manufacturing of Cell & Gene Therapies. Their mission is to support rapid and cost-effective introduction of new advanced therapy products to the market. Their cell processing platform leverages a proprietary design and automation to bring all functionalities required for on-demand and at-scale manufacturing of cell therapies in a single device. www.limula.ch About LifeX Ventures ‍LifeX Ventures is a New York-based venture capital firm investing in global visionary entrepreneurs using software and AI to develop transformational solutions that will extend the life of humans and the planet. With its $100M debut fund, LifeX is targeting the two largest sectors in the world: People (bio/health) and Planet (climate), where Software and AI suddenly matter. ‍www.lifex.vc About Verve Ventures Verve Ventures is one of the most active venture investors in Europe with over 140 science and technology-driven startups in its portfolio. Verve Ventures’ dedicated team helps startups with their most pressing needs such as hiring, client introductions, and an expert network of high-profile individuals. www.verve.vc About Zühlke Ventures Zühlke Ventures is an early stage venture capital investor with focus on HealthTech. Zühlke Ventures’s investment is paired with actionable expertise for finding product-market-fit, for developing and deploying novel products, and for entering international markets. www.zuehlke.com/en/about-us/ventures About Oxford Seed Fund Oxford Seed Fund, run by the Entrepreneurship Centre at Saïd Business School is the largest student-led VC fund outside of North America, investing in top Oxford-affiliated technology enabled pre-seed and seed stage companies. Supporting them with access to funding, talent, skills and networks. The Fund deploys £600,000+ per year across 10+ companies. https://www.sbs.ox.ac.uk/research/centres-and-initiatives/entrepreneurship-centre/oxford-seed-fund About Lichtsteiner Foundation The Lichtsteiner Foundation supports pioneers and early-stage startups in the field of health (medical technology, biotechnology, life science, mental health, public health and wellbeing) in order to improve people’s health in a sustainable way. https://lichtsteinerfoundation.org/ About W.A. de Vigier Foundation Since the foundation’s establishment in 1987, the goal of the W.A. de Vigier Foundation has been to actively invigorate business development and further provide direct financial support to young people with innovative business ideas wishing to build performance and growth-oriented businesses in Switzerland. Until today, the W.A. de Vigier Foundation has awarded CHF 14.3 million in seed capital to Swiss startups. https://devigier.ch/ Contact Details Limula Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://limula.ch/

May 21, 2024 09:00 AM Eastern Daylight Time

Image

1 2 3 4 5 ... 91